Eli Lilly and Company to Invest $150 Million in Singapore R&D Unit
SINGAPORE, March 26 (Reuters) - Eli Lilly and Co. (LLY.N: Quote, Profile , Research) said on Monday it would invest $150 million in its existing research and development (R&D) facility in Singapore to develop drugs for cancer and diabetes.